HOME >> BIOLOGY >> NEWS
Phase III clinical program evaluates lubiprostone

BETHESDA, MD May 16, 2005 Takeda Pharmaceuticals North America (TPNA) and Sucampo Pharmaceuticals announced the initiation of a phase III clinical development program for lubiprostone in patients with constipation-predominant irritable bowel syndrome (IBS-C). Enrollment for these trials begins this month. Lubiprostone is an investigational compound currently being evaluated by the FDA for the treatment of chronic idiopathic constipation and associated pain and bloating in adults.

The IBS-C clinical development program will include two phase III trials. Each trial will examine more than 500 patients for 12 weeks to evaluate the safety and efficacy of lubiprostone.

"Irritable bowel syndrome is a condition that can impact a person's quality of life, but is currently addressed by few available therapies," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine, and principal investigator. "Based on results from our phase II study, we believe lubiprostone may have the potential to treat IBS-C, and thus offer a new option for people living with irritable bowel syndrome."

The program includes two double-blind, randomized phase III clinical trials with a treatment period of 12 weeks, taking place at up to 130 sites around the United States. A previous phase II study in IBS-C patients evaluated the effectiveness across a range of doses. Additionally, studies of lubiprostone in chronic constipation have achieved clinical endpoints of relief of constipation and associated pain and bloating and demonstrated tolerability, regardless of gender.

Lubiprostone is a chloride channel activator, a novel compound with a unique mechanism of action. Taken orally, the agent has been shown to work locally and specifically in the GI tract by activating a specific chloride channel (CLC2). Chloride channels are proteins that carry chloride on cells lining the small intestine. When activated, these cells increase in
'"/>


16-May-2005


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
3. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
6. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
7. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
8. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
9. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
10. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
11. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
Cached News: